ultra-long-acting basal insulin/fast-acting insulin aspart (GZR101) / Gan & Lee Pharma - LARVOL DELTA

Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes (clinicaltrials.gov) - P2 | N=300 | Not yet recruiting | Sponsor: Gan & Lee Pharmaceuticals.

New P2 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

GZR101, a Novel Premixed Insulin for the Treatment of Diabetes Mellitus. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "This study evaluated insulin GZR33 (GZR33), an ultra-long basal insulin, and insulin GZR101 (GZR101), which is a premix of GZR33 and postprandial insulin aspart...Potency was tested in vivo in streptozotocin-induced T1DM rats and db/db T2DM mice, using insulin degludec (degludec, IDeg) and insulin degludec/insulin aspart (IDegAsp) as controls...Therefore, GZR101 provides a promising once-daily premixed insulin candidate with potential to enhance glycemic control and patient adherence. Clinical trial number: not applicable."

Journal • Diabetes • Metabolic Disorders • Type 1 Diabetes Mellitus • Type 2 Diabetes Mellitus • IR

A Trial Comparing Efficacy and Safety of GZR101 and IDegAsp in Insulin Naïve or Insulin Treated Subjects with T2DM (clinicaltrials.gov) - P2 | N=153 | Completed | Sponsor: Gan and Lee Pharmaceuticals, USA | Enrolling by invitation ➔ Completed

Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus